Contraception
Volume 73, Issue 4 , Pages 420-430 , April 2006

Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second-trimester pregnancy

  • Ashlesha Patel

      Affiliations

    • Department of Obstetrics and Gynecology, John H. Stroger Jr. Hospital of Cook County, Chicago, IL 60612, USA
    • Medical Affairs Division, Planned Parenthood Federation of America, New York, NY 10001, USA
    • Corresponding Author InformationCorresponding author. Department of Obstetrics and Gynecology, 5th Floor, John H. Stroger Jr. Hospital, 1901 W Polk, Chicago, IL 60612, USA. Tel.: +1 312 740 3984; fax: +1 312 864 9269.
    • ,
  • Elizabeth Talmont

      Affiliations

    • Medical Affairs Division, Planned Parenthood Federation of America, New York, NY 10001, USA
    • ,
  • Johanna Morfesis

      Affiliations

    • Medical Affairs Division, Planned Parenthood Federation of America, New York, NY 10001, USA
    • ,
  • Murray Pelta

      Affiliations

    • Planned Parenthood Chicago Area, Chicago, IL 60603, USA
    • ,
  • Mary Gatter

      Affiliations

    • Planned Parenthood Los Angeles, Los Angeles, CA 90033, USA
    • ,
  • Michael R. Momtaz

      Affiliations

    • Planned Parenthood of New York City, New York, NY 10012, USA
    • ,
  • Harry Piotrowski

      Affiliations

    • Medical Affairs Division, Planned Parenthood Federation of America, New York, NY 10001, USA
    • ,
  • Vanessa Cullins

      Affiliations

    • Medical Affairs Division, Planned Parenthood Federation of America, New York, NY 10001, USA
    • ,
  • the Planned Parenthood Federation of America Buccal Misoprostol Waiver Group

      Affiliations

    • Planned Parenthood of New York City, New York, NY 10012, USA

Received 19 January 2005 ,Revised 13 September 2005 ,Accepted 7 October 2005.

References 

  1. Grimes DA, Schulz K. Morbidity and mortality from second trimester abortions. J Reprod Med. 1985;30:505–514
  2. Carbonell JL, Velazco A, Rodriguez Y, et al. Oral versus vaginal misoprostol for cervical priming in first-trimester abortion: a randomized trial. Eur Contracept Reprod Health Care. 2001;6:134–140
  3. Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl J Med. 2001;344:38–47
  4. Meckstroth K, Darney P. Prostaglandins for first trimester termination. Best Pract Res Clin Obstet Gynaecol. 2003;17:745–763
  5. Tang O, Mok KH, Ho PC. A randomized study comparing the use of sublingual to vaginal misoprostol for pre-operative cervical priming prior to surgical termination of pregnancy in the first trimester. Hum Reprod. 2004;19:1101–1104
  6. Singh K, Fong YF, Prasad NV, Dong F. Evacuation interval after vaginal misoprostol for preabortion cervical priming: a randomized trial. Obstet Gynecol. 1999;94:431–434
  7. MacIsaac L, Grossman D, Balistreri E, Darney P. A randomized controlled trial of laminaria, oral misoprostol, and vaginal misoprostol before abortion. Obstet Gynecol. 1999;93:766–770
  8. Jain JK, Kuo J, Mishell DR. A comparison of two dosing regimens of intravaginal misoprostol for second-trimester pregnancy termination. Obstet Gynecol. 1999;93:571–575
  9. Todd CS, Soler M, Castleman L, Rogers MK, Blumenthal PD. Buccal misoprostol as cervical preparation for second trimester pregnancy termination. Contraception. 2002;65:415–418
  10. FDA CFR, Title 21, Part 312.32 Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm. Retrieved June 7, 2005.
  11. Saxena P, Salham S, Sarda N. Role of sublingual misoprostol for cervical ripening prior to vacuum aspiration in first trimester interruption of pregnancy. Contraception. 2003;67:213–217
  12. Schulz KF, Grimes DA, Cates W. Measures to prevent cervical injury during suction curettage abortion. Lancet. 1983;1:1182–1185
  13. Bartlett LA, Berg CJ, Shulman HB, et al. Risk factors for legal induced abortion-related mortality in the United States. Obstet Gynecol. 2004;103:729–737
  14. Hern W. Laminaria versus Dilapan osmotic cervical dilators for outpatient dilation and evacuation abortion: randomized cohort comparison of 1001 patients. Am J Obstet Gynecol. 1994;171:1324–1328
  15. Scheepers HCJ, Van Erp EJM, Van Den Bergh AS. Use of misoprostol in first and second trimester abortion: a review. Obstet Gynecol Surv. 1999;54:592–600
  16. Gottlieb C, Lundstrom-Lindstedt V, Swahn ML, Bygdeman M. Vacuum aspiration for termination of early second trimester pregnancy after treatment with vaginal prostaglandin. Acta Obstet Gynecol Scand. 1991;70:41–45
  17. Ho PC, Ngai SW, Liu KL, Wong GC, Lee SW. Vaginal misoprostol compared with oral misoprostol in termination of second-trimester pregnancy. Obstet Gynecol. 1997;90:735–738
  18. Grimes DA. Method, weeks of gestation key in abortion complications. Contracept Technol Update. 1980;1:96–97
  19. Grimes DA, Schulz KF, Cates WJ. Prevention of uterine perforation during curettage abortion. JAMA. 1984;251:2108–2111
  20. Wing DA, Lovett K, Paul RH. Disruption of prior uterine incision following misoprostol for labor induction in women with previous cesarean delivery. Obstet Gynecol. 1998;91:828–830
  21. Daskalakis GJ, Mesogitis SA, Papantoniou NE, Moulopoulos GG, Papapanagiotou AA, Antsaklis AJ. Misoprostol for second trimester pregnancy termination in women with prior caesarean section. BJOG. 2005;112:97–99
  22. Dickinson JE. Misoprostol for second-trimester pregnancy termination in women with a prior cesarean delivery. Obstet Gynecol. 2005;105:352–356
  23. Henshaw SK, Finer LB. The accessibility of abortion services in the United States, 2001. Perspect Sex Reprod Health. 2003;35:16–24
  24. Strauss ST, Herndon J, Chang J, et al. Abortion surveillance―United States, 2001. CDC surveillance summaries, November 26, 2004. MMWR Morb Mortal Wkly Rep. 2004;53:1–32

PII: S0010-7824(05)00421-X

doi: 10.1016/j.contraception.2005.10.004

Contraception
Volume 73, Issue 4 , Pages 420-430 , April 2006

Article Tools